濮阳东方男科医院价格合理濮阳东方男科医院割包皮手术口碑好吗,濮阳东方妇科医院看病专业吗,濮阳东方医院男科割包皮评价比较高,濮阳东方男科医院怎么走,濮阳东方上班时间,濮阳市东方医院评价好不好,濮阳东方医院妇科收费与服务

SAN FRANCISCO, Aug. 22 (Xinhua) -- Hewlett-Packard (HP) on Monday unveiled a new business desktop computer, days after the world's largest personal computer (PC) maker announced its plan to sell its PC business.The company said the new model, HP Compaq 8200 Elite All-in-One Business Desktop, is the industry's first all-in-one PC that integrates Intel's second-generation Core vPro technology, which can deliver up to 40 percent better performance, 15 percent faster hard drive access and reduced downtime via remote information technology management."Another industry first in our Elite desktop family demonstrates our commitment to engineering excellence and underscores our global leadership in secure, enterprise computing, " Jeff Groudan, HP's director of commercial desktop marketing, said in a statement.HP said the new computer is available now in the United States. It starts at the price of 999 U.S. dollars, and comes with a standard three-year warranty.Last Thursday the company announced that it is considering a full or partial separation of its PC business through a spin-off or other transactions, a process that HP estimates may take about 12 to 18 months.

BEIJING, Sept. 2 (Xinhuanet) -- Insomnia costs average U.S. worker 11.3 days, or 2,280 dollars, in lost productivity each year, according to a new study published in journal Sleep.The total cost to the nation is 63.2 billion dollars annually, the study said.Researchers analyzed information about sleep habits and work performance from 7,428 workers taking part in Harvard Medical School's American Insomnia Study survey in 2008-09.As a result, 23.2 percent of the participants suffered insomnia, characterized by a hard time falling or staying asleep.Moreover, insomnia rates were 19.9 percent for those with less than a high school education and 21.5 percent for college graduates."We were shocked by the enormous impact insomnia has on the average person's life," said Ronald C. Kessler, a lead author and a psychiatric epidemiologist at Harvard Medical School."It's an underappreciated problem. Americans are not missing work because of insomnia. They are still going to their jobs but accomplishing less because they're tired," Kessler noted.Employers usually ignore the consequences of insomnia because it's not considered an illness resulting in workers' absenteeism.But the high cost of lost sleep identified in this study indicates that employers need to take it more seriously.

LOS ANGELES, July 18 (Xinhua) -- At least 70 genetic mutations may be involved in the formation of colon cancer, far more than scientists previously thought, a new study suggests.The study by researchers at University of Texas (UT) Southwestern Medical Center contradicts previous thinking that only a few mutated genes may play a role in the development of colon cancer."The ways we've been treating patients up to now is to just go after one target when we should be going after three to four different pathways simultaneously," said Dr. Jerry W. Shay, vice chairman and professor of cell biology at UT Southwestern.The new study identified 65 candidate genes and at least five passenger genes whose mutations play significant roles in cancer development. Inactivating the function of any of these tumor- suppressing genes led to a key step in cancer development called anchorage-independent growth, meaning cells piled up on top of each other rather than aligning neatly.According to previous studies, there were 151 candidate genes and that mutations in just eight to 15 of them would lead to cancer. There were 700 other genes classified as passenger genes whose mutations were incidental to cancer growth.Current cancer treatments target just one or two known cancer- driver genes. While patients may get transient tumor burden reduction, almost universally tumor growth returns."Those numbers are dead wrong," Dr. Shay said, suggesting a new approach to colon cancer treatments targeting multiple genes and pathways simultaneously.The next step is further research to classify more accurately which genes drive cancer and which are merely passengers, the researchers said.Study findings were published in the July 2011 Cancer Research (Priority Reports).

MOSCOW, Aug. 24 (Xinhua) -- A Russian Progress cargo ship crashed into Siberia after failing to reach the right orbit Wednesday. The crash marked the second failure in space launch in less than a week and the third in this year, prompting local media to suspect a major reshuffle in Russia's space industry.UNPRECEDENTED FAILUREThe Progress M-12M unmanned freighter was launched to the International Space Station from Baikonur space center in Kazakhstan on Wednesday. It was expected to reach a near-Earth orbit in about nine minutes after launch.However, after the 325th second of the flight, which was just a few seconds before the vessel should reach the orbit, the ground control center lost it.Russian space agency Roscosmos confirmed later that the cargo ship failed to reach the orbit and fell down. Russian Progress M-12M cargo ship is launched to the International Space Station from Baikonur space center in Kazakhstan on Wednesday, Aug. 24, 2011. It has failed to reach the orbit, the Interfax news agency reported.The malfunction of the Soyuz-U rocket's engine was generally believed to be the cause of the accident, according to local media.A source in the space industry said the spaceship had sent a breakdown report while separating from the Soyuz rocket.Some unconfirmed reports said the fuel tank of the booster leaked and the engine was automatically turned off to avoid explosion.The wreckage of the Progress cargo ship has already fallen in southern Siberia's Altai Republic, where a big explosion was heard by locals, reported RIA Novosti news agency.A state investigation committee has been formed to look into the first ever loss of a Progress freighter.CONCERNS OVER FUTUREThe unprecedented accident raised concerns over the reserves of the six crew members on board the ISS.The ship was loaded with over 3.5 tons of supplies for the ISS, including scientific materials, oxygen, water and food.According to Russia's Ground Control, the loss of these supplies will not affect the ISS crew as there are enough stocks of necessities for two to three months.Also, there is no need for premature return of the crew, said Vladimir Solovyov, a space official.However, it still casts some shadow over the ISS program that relies on Russia exclusively following the retirement of U.S. shuttles.A source from the Russian space industry said the scheduled launches of the Soyuz rockets are likely to be suspended until the reasons of the accident are established.This means that current crew members of the ISS would likely stay longer in the space than planned, as the new members might not be able to replace them on schedule, the source explained. Solovyov said the launch of the next Progress is scheduled for October 28.So far, Roscosmos has refrained from comments regarding the possible halt in manned missions aboard Soyuz carrier rockets."Comments will follow. Now it is necessary to determine the causes of today's abortive launch of a Soyuz-u carrier rocket with the Progress M-2M transport ship," Roscosmos told Itar-Tass news agency.Local media raised the prospect of a major reshuffle in Russia' s space industry as the country has lost a total of six space vehicles over the past nine months.On Aug. 18, a carrier rocket Proton-M failed to deliver to the orbit communication satellite Express-AM4. Earlier in February, Russia had lost a satellite named Geo-IK2.In December 2010, a booster malfunction resulted in the loss of three satellites in the global positioning and navigation system GLONASS.

New York, Sept. 23 (Xinhua) -- A Chinese scientist was presented a prestigious U.S. award on Friday for the discovery of artemisinin, a drug therapy for malaria that has saved millions of lives across the globe, especially in the developing world. Pharmacologist Tu Youyou, 81, became the first scientist on the Chinese mainland to win Lasker Award, known as "America's Nobels" for their knack of gaining future recognition by the Nobel committee.Tu, a scientist at the China Academy of Chinese Medical Sciences in Beijing, pioneered a new approach to malaria treatment that has benefited hundreds of millions of people and promises to benefit many times more. By applying modern techniques and rigor to a heritage provided by 5000 years of Chinese traditional practitioners, she has delivered its riches into the 21st century."Not often in the history of clinical medicine can we celebrate a discovery that has eased the pain and distress of hundreds of millions of people and saved the lives of countless numbers of people, particularly children, in over 100 countries," Lucy Shapiro, a member of the award jury and professor of Stanford University, said while describing Tu' s discovery.Shapiro said the discovery, chemical identification, and validation of artemisinin, a highly effective anti-malarial drug, is largely due to the "scientific insight, vision and dogged determination" of Professor Tu and her team. She thought Professor Tu's work has provided the world with arguably the most important pharmaceutical intervention in the last half century."The discovery of artemisinin is a gift to mankind from traditional Chinese medicine," Tu said while receiving the award. "Continuous exploration and development of traditional medicine will, without doubt, bring more medicines to the world."